News Releases

SEATTLE --(BUSINESS WIRE)--Oct. 23, 2017-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune diseases and cancer, today announced it has extended the research term of its worldwide research and license agreement with Kite, a

SEATTLE --(BUSINESS WIRE)--Oct. 16, 2017-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced planned poster presentations highlighting recent data at the following scientific

SEATTLE --(BUSINESS WIRE)--Sep. 20, 2017-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced a planned poster presentation highlighting recent data from a preclinical study

SEATTLE --(BUSINESS WIRE)--Sep. 13, 2017-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on the development of treatments for autoimmune/inflammatory diseases and cancer, announced today that the company will present at the Ladenburg Thalmann 2017 Healthcare

- Commences Trading on NASDAQ Global Market on July 25, 2017 under Ticker Symbol “ALPN” - - Utilizes Novel Protein-Based Immunotherapy Discovery Platform Focused on Developing Therapeutics for the Potential Treatment of Inflammatory Diseases and Cancer - - Approximately $90 Million in Cash and Cash

Boulder, CO, July 20, 2017 – Nivalis Therapeutics, Inc. (Nivalis) (Nasdaq:NVLS) announced today that, based upon the final vote count certified by the independent inspector of elections for the special meeting of stockholders held July 19, 2017, its stockholders approved all of the merger-related

SEATTLE, Wash., June 14, 2017 – Alpine Immune Sciences, Inc. (Alpine), a biotechnology company developing a next-generation immune modulation platform, today announced results from a preclinical study evaluating first-generation variant Ig domains (vIgDs™) from the company’s lead program, ALPN-101.

– Plan to Accelerate Development of Novel Immunotherapies Focused on Inflammation and Immuno-Oncology – – Combined Company Well Capitalized with $90 Million in Funding to Advance Discovery and Development – – Existing Investors OrbiMed Advisors, Frazier Healthcare Partners, and Alpine BioVentures

The large number of Immunoglobulin Super Family (IgSF) receptors on immune cells and tumors are attractive targets for development of cancer immunotherapies. While nearly all commercial strategies targeting this family are focused on antibody based biologics, we have developed a novel affinity